Advertisement

Cancer Immunology, Immunotherapy

, Volume 68, Issue 2, pp 221–232 | Cite as

Stromal interleukin-33 promotes regulatory T cell-mediated immunosuppression in head and neck squamous cell carcinoma and correlates with poor prognosis

  • Yi-hui Wen
  • Han-qing Lin
  • Hang Li
  • Yi Zhao
  • Vivian Wai Yan Lui
  • Lin Chen
  • Xing-mei Wu
  • Wei SunEmail author
  • Wei-ping WenEmail author
Original Article

Abstract

Regulatory T cells (Tregs) mediate immunosuppressive signals that can contribute to the progression of head and neck squamous cell carcinoma (HNSCC). Interleukin-33 (IL-33) is defined as an ‘alarmin’, an endogenous factor that is expressed during tissue and cell damage, which has been shown to promote Treg proliferation in non-lymphoid organs. However, the interaction between IL-33 and Tregs in the HNSCC tumor microenvironment remains uncertain. In this study, we examined IL-33+ and Foxp3+ cells by immunohistochemistry in 68 laryngeal squamous cell cancer patients, followed by functional analysis of IL-33 in Tregs. In addition, the suppressive function of Tregs was assessed by cell proliferation assays. The level of stromal IL-33 was significantly upregulated in advanced versus early stage HNSCC patients and positively correlated with Foxp3+ Treg infiltration as well as a poor prognosis. ST2 is regarded as the only receptor of IL-33. Infiltrated ST2-expressing Tregs were responsive to IL-33, and the percentage of Tregs was increased upon IL-33 stimulation. Functional investigation demonstrated that IL-33 increased the proportion of Foxp3+GATA3+ Tregs and improved the suppressive functions of Tregs by inducing IL-10 and TGF-β1 as well as decreasing the proliferation of responder T cells. Blockade of ST2 abrogated the immunosuppression caused by IL-33. Our data demonstrate that stromal IL-33 both expands the Treg population and enhances their functions in the tumor microenvironment. Furthermore, stromal IL-33 has prognostic value for tumor progression. Thus, stromal IL-33 is a potential target for future HNSCC immunotherapy.

Keywords

Interleukin-33 Regulatory T cells Head and neck squamous cell carcinoma Prognosis Tumor microenvironment 

Abbreviations

LSCC

Laryngeal squamous cell carcinoma

TSN

Tumor supernatant

Notes

Author contributions

YW, WS, and WW conceived and designed the experiments. HL and YW performed the experiments. HL and YZ evaluated immunohistochemistry. XW, LC, and WS made important contributions to collecting blood and tissue samples. HL, YW, and WW wrote the manuscript. VWYL commented on and edited the manuscript. All authors read and approved the final manuscript.

Funding

Yi-hui Wen was supported by grants from the Natural Science Foundation of Guangdong Province, China (Nos. 2018A030313667, 2017A030310362, and 2015A030310236). Wei-ping Wen was supported by Guangzhou Science and Technology Programme (No. 201605030003) and the Sun Yat-Sen University 5010 Plan (2010004). Vivian Wai Yan Lui was supported by the General Research Fund from the Research Grant Council, Hong Kong (No. 1711484 and No. 17121616), Theme-based Research from the Research Grant Council, Hong Kong (T12-401/13-R), and a Direct Grant for Research (No. 2016.095), the Chinese University of Hong Kong. Wei Sun was supported by the Natural Science Foundation of China (No. 81602365) and Natural Science Foundation of Guangdong Province, China (No. 2016A030310153).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China (Approval no. 2012-349). Informed consent was obtained from all participants prior to enrollment in the study.

Supplementary material

262_2018_2265_MOESM1_ESM.pdf (327 kb)
Supplementary material 1 (PDF 326 KB)

References

  1. 1.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108CrossRefGoogle Scholar
  2. 2.
    Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856–1867CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Harrington KJ, Ferris RL, Blumenschein G Jr, Fayette CAD, Licitra J, Kasper L, Even S, Vokes C, Worden EE, Saba F, Kiyota NF, Haddad N, Tahara R, Grunwald M, Shaw V, Monga JW, Lynch M, Taylor M, DeRosa F, Morrissey M, Cocks L, Gillison K, Guigay ML J (2017) Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol 18:1104–1115CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Li Q, Prince ME, Moyer JS (2015) Immunotherapy for head and neck squamous cell carcinoma. Oral Oncol 51:299–304CrossRefPubMedGoogle Scholar
  5. 5.
    Ferris RL (2015) Immunology and immunotherapy of head and neck cancer. J Clin Oncol 33::3293–3304CrossRefGoogle Scholar
  6. 6.
    Houghton AN, Guevara-Patino JA (2004) Immune recognition of self in immunity against cancer. J Clin Invest 114:468–471CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Mandal R, Senbabaoglu Y, Desrichard A, Havel JJ, Dalin MG, Riaz N, Lee KW, Ganly I, Hakimi AA, Chan TA, Morris LG (2016) The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight 1:e89829CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6::295–307CrossRefGoogle Scholar
  9. 9.
    Sun W, Li WJ, Wei FQ, Wong TS, Lei WB, Zhu XL, Li J, Wen WP (2016) Blockade of MCP-1/CCR4 signaling-induced recruitment of activated regulatory cells evokes an antitumor immune response in head and neck squamous cell carcinoma. Oncotarget 7:37714–37727PubMedPubMedCentralGoogle Scholar
  10. 10.
    Sun W, Wei FQ, Li WJ, Wei JW, Zhong H, Wen YH, Lei WB, Chen L, Li H, Lin HQ, Iqbal M, Wen WP (2017) A positive-feedback loop between tumour infiltrating activated Treg cells and type 2-skewed macrophages is essential for progression of laryngeal squamous cell carcinoma. Br J Cancer 117:1631–1643CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Cayrol C, Girard JP (2014) IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol 31:31–37CrossRefPubMedGoogle Scholar
  12. 12.
    Matzinger P (2002) The danger model: a renewed sense of self. Science 296:301–305CrossRefGoogle Scholar
  13. 13.
    Peine M, Marek RM, Lohning M (2016) IL-33 in T cell differentiation, function, and immune homeostasis. Trends Immunol 37:321–333CrossRefPubMedGoogle Scholar
  14. 14.
    Guo L, Wei G, Zhu J, Liao W, Leonard WJ, Zhao K, Paul W (2009) IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells. Proc Natl Acad Sci USA 106:13463–13468CrossRefPubMedGoogle Scholar
  15. 15.
    Maneechotesuwan K, Xin Y, Ito K, Jazrawi E, Lee KY, Usmani OS, Barnes PJ, Adcock IM (2007) Regulation of Th2 cytokine genes by p38 MAPK-mediated phosphorylation of GATA-3. J Immunol 178:2491–2498CrossRefPubMedGoogle Scholar
  16. 16.
    Schiering C, Krausgruber T, Chomka A, Frohlich A, Adelmann K, Wohlfert EA, Pott J, Griseri T, Bollrath J, Hegazy AN, Harrison OJ, Owens BMJ, Lohning M, Belkaid Y, Fallon PG, Powrie F (2014) The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 513:564–568CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Xiao P, Wan X, Cui B, Liu Y, Qiu C, Rong J, Zheng M, Song Y, Chen L, He J, Tan Q, Wang X, Shao X, Liu Y, Cao X, Wang Q (2016) Interleukin 33 in tumor microenvironment is crucial for the accumulation and function of myeloid-derived suppressor cells. Oncoimmunology 5:e1063772CrossRefPubMedGoogle Scholar
  18. 18.
    Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic MZ, Arsenijevic NN, Lukic ML (2014) Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer 134:1669–1682CrossRefPubMedGoogle Scholar
  19. 19.
    Brunner SM, Rubner C, Kesselring R, Martin M, Griesshammer E, Ruemmele P, Stempfl T, Teufel A, Schlitt HJ, Fichtner-Feigl S (2015) Tumor-infiltrating, interleukin-33-producing effector-memory CD8(+) T cells in resected hepatocellular carcinoma prolong patient survival. Hepatology 61:1957–1967CrossRefPubMedGoogle Scholar
  20. 20.
    Kuang DM, Peng C, Zhao Q, Wu Y, Chen MS, Zheng L (2010) Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology 51:154–164CrossRefPubMedGoogle Scholar
  21. 21.
    Wei FQ, Sun W, Wong TS, Gao W, Wen YH, Wei JW, Wei Y, Wen WP (2016) Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination. J Exp Clin Cancer Res 35:18CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Vasanthakumar A, Moro K, Xin A, Liao Y, Gloury R, Kawamoto S, Fagarasan S, Mielke LA, Afshar-Sterle S, Masters SL, Nakae S, Saito H, Wentworth JM, Li P, Liao W, Leonard WJ, Smyth GK, Shi W, Nutt SL, Koyasu S, Kallies A (2015) The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue-resident regulatory T cells. Nat Immunol 16:276–285CrossRefGoogle Scholar
  23. 23.
    Kolodin D, van Panhuys N, Li C, Magnuson AM, Cipolletta D, Miller CM, Wagers A, Germain RN, Benoist C, Mathis D (2015) Antigen- and cytokine-driven accumulation of regulatory T cells in visceral adipose tissue of lean mice. Cell Metab 21:543–557CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949CrossRefPubMedGoogle Scholar
  25. 25.
    Sun W, Li WJ, Wu CY, Zhong H, Wen WP (2014) CD45RA-Foxp3high but not CD45RA + Foxp3low suppressive T regulatory cells increased in the peripheral circulation of patients with head and neck squamous cell carcinoma and correlated with tumor progression. J Exp Clin Cancer Res 33:35CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Sun W, Li WJ, Fu QL, Wu CY, Lin JZ, Zhu XL, Hou WJ, Wei Y, Wen YH, Wang YJ, Wen WP (2015) Functionally distinct subsets of CD4(+) regulatory T cells in patients with laryngeal squamous cell carcinoma are indicative of immune deregulation and disease progression. Oncol Rep 33:354–362CrossRefPubMedGoogle Scholar
  27. 27.
    Chen SF, Nieh S, Jao SW, Wu MZ, Liu CL, Chang YC, Lin YS (2013) The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma. J Pathol 231:180–189CrossRefPubMedGoogle Scholar
  28. 28.
    Ishikawa K, Yagi-Nakanishi S, Nakanishi Y, Kondo S, Tsuji A, Endo K, Wakisaka N, Murono S, Yoshizaki T (2014) Expression of interleukin-33 is correlated with poor prognosis of patients with squamous cell carcinoma of the tongue. Auris Nasus Larynx 41:552–557CrossRefPubMedGoogle Scholar
  29. 29.
    Matta BM, Lott JM, Mathews LR, Liu Q, Rosborough BR, Blazar BR, Turnquist HR (2014) IL-33 is an unconventional Alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2 + regulatory T cells. J Immunol 193:4010–4020CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Molofsky AB, Van Gool F, Liang HE, Van Dyken SJ, Nussbaum JC, Lee J, Bluestone JA, Locksley RM (2015) Interleukin-33 and interferon-gamma counter-regulate group 2 innate lymphoid cell activation during immune perturbation. Immunity 43:161–174CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Moussion C, Ortega N, Girard JP (2008) The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’? PLoS One 3:e3331CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Liu J, Shen JX, Hu JL, Huang WH, Zhang GJ (2014) Significance of interleukin-33 and its related cytokines in patients with breast cancers. Front Immunol 5:141CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Chen CC, Kobayashi T, Iijima K, Hsu FC, Kita H (2017) IL-33 dysregulates regulatory T cells and impairs established immunologic tolerance in the lungs. J Allergy Clin Immunol 140::1351–1363 e1357CrossRefGoogle Scholar
  34. 34.
    Nawijn MC, Dingjan GM, Ferreira R, Lambrecht BN, Karis A, Grosveld F, Savelkoul H, Hendriks RW (2001) Enforced expression of GATA-3 in transgenic mice inhibits Th1 differentiation and induces the formation of a T1/ST2-expressing Th2-committed T cell compartment in vivo. J Immunol 167:724–732CrossRefPubMedGoogle Scholar
  35. 35.
    Gachter T, Werenskiold AK, Klemenz R (1996) Transcription of the interleukin-1 receptor-related T1 gene is initiated at different promoters in mast cells and fibroblasts. J Biol Chem 271:124–129CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Yi-hui Wen
    • 1
    • 2
  • Han-qing Lin
    • 1
    • 2
  • Hang Li
    • 1
    • 2
  • Yi Zhao
    • 1
    • 2
  • Vivian Wai Yan Lui
    • 3
  • Lin Chen
    • 1
    • 2
  • Xing-mei Wu
    • 1
    • 2
  • Wei Sun
    • 1
    • 2
    Email author
  • Wei-ping Wen
    • 1
    • 2
    Email author
  1. 1.Department of OtolaryngologyThe First Affiliated Hospital of Sun Yat-sen UniversityGuangzhouChina
  2. 2.Guangzhou Key Laboratory of OtorhinolaryngologyGuangzhouChina
  3. 3.School of Biomedical Sciences, Faculty of MedicineThe Chinese University of Hong KongHong KongChina

Personalised recommendations